Stevens Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Stevens Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-55,258	Closed	-$193K	–	1379
2014 Q1	$193K	Buy	+55,258	New	+$245K	0.01%	934
2013 Q4	–	Sell	-74,934	Closed	-$304K	–	1299
2013 Q3	$304K	Buy	+74,934	New	+$327K	0.01%	781

Other funds holding ATRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WHI

William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Stevens Capital Management's ATRS Position: Q2 2014 in Review

Stevens Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2014, closing a stake of 55,258 shares — an estimated $193K sold.

Stevens Capital Management first reported a position in ATRS in Q3 2013 and held it in 2 quarters. The position peaked at $304K in Q3 2013. 85 funds tracked by Wall St. Rank hold ATRS as of Q2 2014.

Stevens Capital Management reported no remaining Antares Pharma, Inc. position as of Q2 2014 after selling out during the quarter.
Stevens Capital Management sold 55,258 Antares Pharma, Inc. shares in Q2 2014, an estimated $193K.
Stevens Capital Management first reported a position in Antares Pharma, Inc. in Q3 2013 and held it in 2 quarters.
Stevens Capital Management's Antares Pharma, Inc. position peaked at $304K in Q3 2013.
85 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2014.

Based on Stevens Capital Management's 13F filing for Q2 2014, filed 12 Aug 2014.